Fa-Au: Dual-Pharmacophore TrxR Inhibitor Data for Cancer Immunotherapy

2.1 KB of CSV data describes a series of dual-pharmacophore thioredoxin reductase (TrxR) inhibitors developed via a traditional Chinese medicine-ligand synergistic strategy. The dataset, authored by Zhongren Xu and last updated in April 2026, likely contains experimental results for the superior compound Fa-Au, which inhibited TrxR, suppressed tumor growth, and remodeled the tumor immune microenvironment.

Use Cases

• Analyzing the relationship between dual-pharmacophore inhibitors and antitumor activity based on the described TrxR inhibition.
• Studying the regulation of the tumor immune microenvironment based on features like M1 macrophage polarization and CD8+ T cell activation.
• Investigating mechanisms of mitochondria-associated ferroptosis based on the described TrxR/GPX4 downregulation.
• Evaluating potential chemoimmunotherapeutic agents based on the described antitumor immune feedback loop.

Strengths

• Data is focused on a novel, specific research area: dual-pharmacophore TrxR inhibitors integrating ferroptosis and antitumor immunity.
• The description provides a detailed mechanistic hypothesis involving the IFN-γ/STAT1/SLC7A11 axis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (2.1 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from a research study.

Freshness

Last updated 2026-04-24 04:04:28; freshness should be verified.